Verrica Pharmaceuticals Inc.
VRCA
$5.23
-$0.12-2.24%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 145.35% | -10.12% | -82.70% | -161.06% | 2,744.51% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 145.35% | -10.12% | -82.70% | -161.06% | 2,744.51% |
| Cost of Revenue | -39.39% | -55.29% | -39.39% | 61.11% | -34.12% |
| Gross Profit | 687.39% | 131.77% | 34.76% | -183.72% | 123.17% |
| SG&A Expenses | -46.42% | -45.85% | -41.87% | -19.80% | 178.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -45.09% | -48.41% | -48.33% | -29.48% | 72.77% |
| Operating Income | 109.93% | 56.29% | 45.01% | 13.43% | -30.91% |
| Income Before Tax | 101.19% | 52.08% | 34.18% | 7.83% | -56.38% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 101.19% | 52.08% | 34.18% | 7.83% | -56.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 101.19% | 52.08% | 34.18% | 7.83% | -56.38% |
| EBIT | 109.93% | 56.29% | 45.01% | 13.43% | -30.91% |
| EBITDA | 110.94% | 56.40% | 45.54% | 14.00% | -30.21% |
| EPS Basic | 100.58% | 76.51% | 54.72% | 9.27% | -54.41% |
| Normalized Basic EPS | 100.58% | 76.51% | 49.78% | 9.27% | -54.41% |
| EPS Diluted | 100.54% | 76.51% | 54.72% | 9.27% | -54.59% |
| Normalized Diluted EPS | 100.58% | 76.51% | 49.78% | 9.27% | -54.41% |
| Average Basic Shares Outstanding | 104.04% | 104.02% | 45.38% | 1.59% | 1.27% |
| Average Diluted Shares Outstanding | 104.09% | 104.02% | 45.38% | 1.59% | 1.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |